

Resource Summary Report

Generated by [NIF](#) on Aug 3, 2026

CT26.WT

RRID:CVCL_7256

Type: Cell Line

Proper Citation

RRID:CVCL_7256

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_7256

Proper Citation: RRID:CVCL_7256

Description: Cell line CT26.WT is a Cancer cell line with a species of origin Mus musculus (Mouse)

Sex: Female

Disease: Mouse colon adenocarcinoma

Defining Citation: [PMID:7722321](#), [PMID:11089883](#), [PMID:24621249](#), [PMID:25277546](#), [PMID:31220119](#)

Category: Cancer cell line

Organism: Mus musculus (Mouse)

Name: CT26.WT

Synonyms: CT-26 WT, CT26.wt, CT26WT

Cross References: BTO:BTO_0006018, CLO:CLO_0002631, ATCC:CRL-2638, BCRC:60447, BCRJ:0402, BioSample:SAMN11397649, CCRID:1101MOU-PUMC000275, CCRID:3101MOUTCM37, ChEMBL-Cells:ChEMBL4513106, ChEMBL-Targets:ChEMBL4513123, CLS:305178, KCB:KCB 201207YJ, PubChem_Cell_line:CVCL_7256, Ubigen:YC-B003, Wikidata:Q54814710

ID: CVCL_7256

Hierarchy: cvcl_7254

Record Creation Time: 20220427T215526+0000

Record Last Update: 20260801T235522+0000

Ratings and Alerts

No rating or validation information has been found for CT26.WT.

No alerts have been found for CT26.WT.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 161 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Arnaut LG, et al. (2026) Flash Photodynamic Therapy - How the Saturation of Photosensitizer Absorption Enables Selective and Deeper Tumor Treatments. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(1), e13199.

Zhan W, et al. (2026) Cathepsin-D-mediated MHC class I degradation contributes to immune evasion in colorectal cancer. *Cell reports. Medicine*, 102534.

Gao H, et al. (2026) Real-Time In Vivo Cellular-Level Imaging During Puncture. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), e15110.

Wang D, et al. (2026) UBE2O-mediated monoubiquitination licenses NLRP6 inflammasome activation in the intestine. *Cell host & microbe*, 34(1), 86.

Galeano Ni??o JL, et al. (2026) Tumor-infiltrating bacteria disrupt cancer epithelial cell interactions and induce cell-cycle arrest. *Cancer cell*, 44(1), 166.

Osaki M, et al. (2025) Soluble CTLA-4 regulates immune homeostasis and promotes resolution of inflammation by suppressing type 1 but allowing type 2 immunity. *Immunity*, 58(4), 889.

Liu Z, et al. (2025) PAR2 deficiency impairs antitumor immunity and attenuates anti-PD1 efficacy in colorectal cancer. *Pharmacological research*, 215, 107721.

Petkov V, et al. (2025) ISCOM-type matrix from beta-escin and glycyrrhizin saponins. *Heliyon*, 11(2), e41935.

Liu X, et al. (2025) The pan-cancer mutational landscape of MLL3 and its impact on prognosis and immunochemotherapy. *Cell reports*, 44(11), 116548.

Huang Y, et al. (2025) CD24-Targeted CAR-T Cells Mediated Long-term Antitumor Efficacy through Activation of Endogenous Tumor Immune Responses. *Molecular cancer therapeutics*, 24(7), 1075.

Li S, et al. (2025) Colon cancer exosome-associated HSP90B1 initiates pre-metastatic niche formation in the liver by polarizing M1 macrophage into M2 phenotype. *Biology*

direct, 20(1), 52.

Shimizu K, et al. (2025) Distinct TAM subset with cross-dressing capability determines the bifurcation of tumor immunity. *Cell reports*, 44(6), 115800.

Li B, et al. (2025) Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis. *Cell*, 188(14), 3823.

Lien HW, et al. (2025) Electromagnetic Wireless Remote Control of Reprogramming Immune Dysfunction via N-Doped Carbon Dots-Mesoporous Silica-Mediated Cuproptosis and Dendritic Cell Retention. *Advanced healthcare materials*, e02817.

Gujar R, et al. (2025) Developing a therapeutic elastase that stimulates anti-tumor immunity by selectively killing cancer cells. *Cell reports. Medicine*, 6(11), 102446.

Niu D, et al. (2025) Local delivery of IL-15 and anti-PD-L1 nanobody by in vitro-transcribed circILNb elicits superior antitumor immunity in cold tumors. *Cell reports. Medicine*, 6(10), 102413.

Qian J, et al. (2025) A CXCR4 partial agonist improves immunotherapy by targeting immunosuppressive neutrophils and cancer-driven granulopoiesis. *Cancer cell*, 43(8), 1512.

Liang B, et al. (2025) Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer. *Molecular cancer therapeutics*, 24(1), 131.

Wu CY, et al. (2025) Glucose restriction shapes pre-metastatic innate immune landscapes in the lung through exosomal TRAIL. *Cell*.

Xie M, et al. (2025) Tumor-resident probiotic *Clostridium butyricum* improves aPD-1 efficacy in colorectal cancer models by inhibiting IL-6-mediated immunosuppression. *Cancer cell*.